Phase 2 Parkinson's Disease Trial, Recruiting NCT06831500 Sponsor: Julien Bally Condition: Parkinson's Disease
Back to Parkinsons Disease

Phase 2 Parkinson's Disease Trial, Recruiting

NCT06831500
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have signed an informed consent form agreeing to take part
  • People aged between 18 and 79 years old
  • People who have been diagnosed with Multiple System Atrophy – Parkinsonian type (MSA-P), confirmed using recognised diagnostic guidelines; OR people diagnosed with Parkinson's Disease (PD) who also experience symptoms of low blood pressure when standing up, as measured by a specific questionnaire called the SCOPA-AUT (questions 14, 15, and 16)
  • People who are currently taking a medication known as Dopamine-Replacement Therapy — specifically Levodopa combined with either Carbidopa or Benserazide

Who may not be able to join:

  • People who are unable to go without their fast-acting Dopamine-Replacement Therapy for at least 12 hours overnight (and whose slow-release or extended-release form of the medication must have been taken at least 24 hours before a scheduled test)
  • People with a known serious heart condition called congestive heart failure, specifically at more advanced stages (grades C and D, or NYHA class III and IV)
  • People with significant memory or thinking difficulties (dementia) related to their MSA-P or Parkinson's Disease diagnosis
  • People with mild thinking or memory difficulties who are not able to fully understand or agree to the consent process
  • People who are currently taking part in another clinical trial
  • People who are pregnant, breastfeeding, or planning to become pregnant

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: +41 79 556 78 19

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Julien Bally
Registry
ClinicalTrials.gov
Start date
18 July 2025
Est. completion
1 November 2026

Where this trial is recruiting

🇨🇭 Switzerland

Primary endpoints

Feasibility of future large-scale double-blind randomized controlled trial (RCT)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov